Institution
I.M. Sechenov First Moscow State Medical University
Education•Moscow, Russia•
About: I.M. Sechenov First Moscow State Medical University is a education organization based out in Moscow, Russia. It is known for research contribution in the topics: Medicine & Population. The organization has 7984 authors who have published 9355 publications receiving 68997 citations.
Topics: Medicine, Population, Cancer, Disease, Blood pressure
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The metal affects mostly the brain by accumulating in specific areas, altering cognitive functions and locomotion, thus severely impacting the health of the exposed organisms.
27 citations
••
I.M. Sechenov First Moscow State Medical University1, Yaroslavl State University2, Universidade Estadual de Londrina3, Albert Einstein College of Medicine4, Peoples' Friendship University of Russia5, Moscow State University6, Innlandet Hospital Trust7, Orenburg State University8, Russian Academy of Sciences9, University of Crete10, Florida A&M University11, Purdue University12
TL;DR: A review of recent findings in the field of Mn-induced neurotoxicity can be found in this article, with an emphasis on the current gaps and future research directions of the field.
Abstract: Understanding of the immediate mechanisms of Mn-induced neurotoxicity is rapidly evolving. We seek to provide a summary of recent findings in the field, with an emphasis to clarify existing gaps and future research directions. We provide, here, a brief review of pertinent discoveries related to Mn-induced neurotoxicity research from the last five years. Significant progress was achieved in understanding the role of Mn transporters, such as SLC39A14, SLC39A8, and SLC30A10, in the regulation of systemic and brain manganese handling. Genetic analysis identified multiple metabolic pathways that could be considered as Mn neurotoxicity targets, including oxidative stress, endoplasmic reticulum stress, apoptosis, neuroinflammation, cell signaling pathways, and interference with neurotransmitter metabolism, to name a few. Recent findings have also demonstrated the impact of Mn exposure on transcriptional regulation of these pathways. There is a significant role of autophagy as a protective mechanism against cytotoxic Mn neurotoxicity, yet also a role for Mn to induce autophagic flux itself and autophagic dysfunction under conditions of decreased Mn bioavailability. This ambivalent role may be at the crossroad of mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis. Yet very recent evidence suggests Mn can have toxic impacts below the no observed adverse effect of Mn-induced mitochondrial dysfunction. The impact of Mn exposure on supramolecular complexes SNARE and NLRP3 inflammasome greatly contributes to Mn-induced synaptic dysfunction and neuroinflammation, respectively. The aforementioned effects might be at least partially mediated by the impact of Mn on α-synuclein accumulation. In addition to Mn-induced synaptic dysfunction, impaired neurotransmission is shown to be mediated by the effects of Mn on neurotransmitter systems and their complex interplay. Although multiple novel mechanisms have been highlighted, additional studies are required to identify the critical targets of Mn-induced neurotoxicity.
27 citations
••
TL;DR: A clinically applicable risk stratification tool with a binary output for risk of developing PDAC (‘elevated’ or ‘normal’).
Abstract: Publisher Copyright: © 2020 Debernardi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
27 citations
••
TL;DR: This work explores combination trials in breast cancer brain metastasis (BCBM), highlighting deficiencies in trial design and underlining promising combination strategies, and concludes that enhancing drug delivery through blood-brain barrier permeable agents may potentiate the overall therapeutic outcomes.
Abstract: Combination therapy has become a cornerstone in cancer treatment to potentiate therapeutic effectiveness and overcome drug resistance and metastasis. In this work, we explore combination trials in breast cancer brain metastasis (BCBM), highlighting deficiencies in trial design and underlining promising combination strategies. On October 31, 2019, we examined ClinicalTrials.gov for interventional and therapeutic clinical trials involving combination therapy for BCBM, without limiting for date or location. Information on trial characteristics was collected. Combination therapies used in trials were analyzed and explored in line with evidence from the medical literature. Sixty-five combination therapy trials were selected (n = 65), constituting less than 0.7% of all breast cancer trials. Most trials (62%) combined ≥2 chemotherapeutic agents. Chemotherapy with radiation was main-stay in 23% of trials. Trastuzumab was mostly used in combination (31%), followed by lapatinib (20%) and capecitabine (15%). Common strategies involved combining tyrosine kinase inhibitors with thymidylate synthase inhibitors (6 trials), dual HER-dimerization inhibitors (3 trials), microtubule inhibitors and tyrosine kinase inhibitors (3 trials), and HER-dimerization inhibitors and tyrosine kinase inhibitors (3 trials). The combination of tucatinib and capecitabine yielded the highest objective response rate (83%) in early phase trials. The triple combination of trastuzumab, tucatinib and capecitabine lowered the risk of disease progression or death by 52% in patients with HER2-positive BCBM. Combining therapeutic agents based on biological mechanisms is necessary to increase the effectiveness of available anti-cancer regimens. Significant survival benefit has yet to be achieved in future combination therapy trials. Enhancing drug delivery through blood-brain barrier permeable agents may potentiate the overall therapeutic outcomes.
27 citations
••
National University of Science and Technology1, South Ural State University2, Joint Institute for Nuclear Research3, Centre national de la recherche scientifique4, Spanish National Research Council5, I.M. Sechenov First Moscow State Medical University6, National Research University of Electronic Technology7, Tanta University8, Zhejiang University9
TL;DR: In this article, the authors investigated the local crystal/magnetic structures of the In-substituted SrFe12−xInxO19 hexaferrites using neutron powder diffraction.
27 citations
Authors
Showing all 8045 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yehuda Shoenfeld | 125 | 1629 | 77195 |
Jatin P. Shah | 119 | 725 | 45680 |
Shahrokh F. Shariat | 118 | 1637 | 58900 |
Vladimir P. Torchilin | 109 | 627 | 58977 |
Klaus-Peter Lesch | 106 | 524 | 50099 |
Jürgen Kurths | 105 | 1038 | 62179 |
Rudolf Valenta | 102 | 748 | 38349 |
Valerian E. Kagan | 97 | 667 | 39888 |
Hans-Uwe Simon | 96 | 461 | 51698 |
Gleb B. Sukhorukov | 96 | 440 | 35549 |
Michael Aschner | 91 | 806 | 32826 |
Alexei Verkhratsky | 89 | 450 | 29788 |
Claudio L. Bassetti | 88 | 524 | 25332 |
Helgi B. Schiöth | 85 | 531 | 28628 |
Angelo Ravelli | 79 | 415 | 23439 |